Commodore Capital’s Palisade Bio PALI Stock Holding History

Commodore Capital’s Portfolio PALI Stock Details PALI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,181,062	Closed	-$12.6M	–	39
2026 Q1	$12.6M	Sell	7,181,062 -4,263,938	-37%	-$7.75M	0.73%	28
2025 Q4	$26.9M	Buy	+11,445,000	New	+$22M	1.79%	22

Other funds holding PALI

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BGI

B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Commodore Capital's PALI Position: Q2 2026 in Review

Commodore Capital sold out of Palisade Bio (PALI) in Q2 2026, closing a stake of 7,181,062 shares — an estimated $12.6M sold.

Commodore Capital first reported a position in PALI in Q4 2025 and held it in 2 quarters. The position peaked at $26.9M in Q4 2025. 124 funds tracked by Wall St. Rank hold PALI as of Q2 2026.

Commodore Capital reported no remaining Palisade Bio position as of Q2 2026 after selling out during the quarter.
Commodore Capital sold 7,181,062 Palisade Bio shares in Q2 2026, an estimated $12.6M.
Commodore Capital first reported a position in Palisade Bio in Q4 2025 and held it in 2 quarters.
Commodore Capital's Palisade Bio position peaked at $26.9M in Q4 2025.
124 funds tracked by Wall St. Rank held Palisade Bio as of Q2 2026.

Based on Commodore Capital's 13F filing for Q2 2026, filed 14 Aug 2026.